BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

Cell death escape is one of the most prominent features of tumor cells and closely linked to
the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic …

Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …

Venetoclax with azacitidine (ven/aza) has emerged as a promising treatment regimen for
acute myeloid leukemia (AML), with a high percentage of clinical remissions in newly …

Venetoclax-based therapy can induce responses in approximately 70% of older previously
untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well …

Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …

We generated ex vivo drug-response and multiomics profiling data for a prospective series
of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision …

Deregulation of the BCL2 gene family plays an important role in the pathogenesis of acute
myeloid leukemia (AML). A BCL2 inhibitor, venetoclax, has received approval from the US …

The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently
transforming acute myeloid leukemia (AML) therapy. However, there is a lack of clinically …

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …